Bacillus Calmette-Guerin therapy for bladder carcinoma in situ: use in a clinical setting
Skaugen, P.
Urologic Nursing 17(2): 69-71
1997
ISSN/ISBN: 1053-816X PMID: 9239141 Document Number: 475615
Document emailed within 1 workday
Related Documents
Okusa, H.; Irie, A.; Chin, I.; Baba, S.; Mitomi, H.; Shitara, T. 2003: Cases of bacillus Calmette-Guerin-induced granulomatous prostatitis and prostatic stromal invasion of the bladder carcinoma in situ, showing similar clinical findings Hinyokika Kiyo. Acta Urologica Japonica 49(9): 555-557Nishino, Y.; Yasuda, M.; Yokoi, S.; Ehara, H.; Yamamoto, N.; Takahashi, Y.; Ishihara, S.; Deguchi, T.; Kawada, Y.; Takeda, A.; Sakai, S.; Takeuchi, T.; Taniguchi, M.; Minoshima, K.; Hamamoto, Y.; Kanimoto, Y.; Nakano, M.; Fujihiro, S.; Nezasa, S.; Matsuda, T.; Nagatani, Y.; Maeda, S.; Tamaki, M.; Saito, A.; Komeda, H. 1999: Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(12): 1869-1873
Jurincic-Winkler, C.; Metz, K.A.; Beuth, J.; Sippel, J.; Klippel, K.F. 1995: Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder Anticancer Research 15(6b): 2771-2776
Tsukagoshi, S. 2003: ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(7): 1027-1038
Shapiro, A.; Ratliff, T.L.; Oakley, D.M.; Catalona, W.J. 1983: Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity Cancer Research 43(4): 1611-1615
Lee, P.P. 2015: Disseminated Bacillus Calmette-Guérin and Susceptibility to Mycobacterial Infections-Implications on Bacillus Calmette-Guérin Vaccinations Annals of the Academy of Medicine Singapore 44(8): 297-301
Mori, H.; Miyaji, B.; Takahashi, M.; Matsuda, K.; Tsuka, H.; Wada, O.; Aoki, Y.; Akino, H.; Muranaka, K.; Kanamaru, H.; Okada, K.; Imamura, Y. 1996: Intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma Hinyokika Kiyo. Acta Urologica Japonica 42(4): 257-261
Vázquez-Lavista, L.G.; Flores-Balcázar, C.H.é; Llorente, L. 2007: The bacillus Calmette-Guérin as immunomodulator in bladder cancer Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 59(2): 146-152
Debruyne, F.M.; Witjes, J.A.; vd Meijden, A.P. 1990: Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview Archivos Espanoles de Urologia 43(Suppl): 133-138
Lamm, D.L.; Harris, S.C.; Gittes, R.F. 1977: Bacillus Calmette-Guérin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors Investigative Urology 14(5): 369-372
Moyano Calvo, J.L.; Sanz Sacristán, J.; Teba del Pino, F.; Fernández Arjona, M.; Peinado Ibarra, F.; Mélon Rey, F.; Herrero Torres, L.; Rabadán Ruiz, M.; Arellano Gañán, R.; Albacete Almodóvar, P. 1995: Calmette-Guerin bacillus in the prophylaxis of superficial bladder tumors. our experience and our doubts Archivos Espanoles de Urologia 48(8): 791-795
Ao, T.; Endo, T.; Shiokawa, H.; Shimura, S.; Adachi, K.; Koshiba, K. 1993: Kidney-conservative surgery followed by bacillus Calmette-Guerin instillation therapy for transitional cell carcinoma of solitary renal pelvis: a case report Hinyokika Kiyo. Acta Urologica Japonica 39(5): 463-465
Iturralde Codina, A.; Beyríe Tamayo, W.; Gozá León, F.; Muñoz, Y.I. 2004: Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes Archivos Espanoles de Urologia 57(6): 606-618
Merrin, C.; Han, T.; Klein, E.; Wajsman, Z.; Murphy, G.P. 1975: Immunotherapy of prostatic carcinoma with bacillus Calmette-Guerin Cancer ChemoTherapy Reports 59(1): 157-163
Goupille, P.; Valat, J.P. 1996: Arthritis after bacillus Calmette-Guérin therapy Journal of Rheumatology 23(8): 1481-1482
De Boer, E.C.; De Jong, W.H.; Steerenberg, P.A.; Van der Meijden, A.P.; Aarden, L.A.; Debruyne, F.M.; Ruitenberg, E.J. 1991: Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin In Vivo 5(6): 671-677
Luo, Y.; Chen, X.; Downs, T.M.; DeWolf, W.C.; O'Donnell, M.A. 1999: IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy Journal of Immunology 162(4): 2399-2405
Flam, T.A.; Chopin, D.K.; Leleu, C.; Abbou, C.C.; Steg, A.; Deslignères, S.; Boccon-Gibod, L. 1990: Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guérin endovesical immunotherapy for superficial bladder tumors European Urology 17(4): 338-342
Milas, L.; Maillefert, J.F.; Michel, F.; Piroth, C.; Wautot, A.; Tavernier, C. 1999: Refractory arthropathy after intravesical bacillus Calmette-Guérin therapy. Usefulness of isoniazide Revue du Rhumatisme 66(2): 106-108
Pearson, J.W.; Chaparas, S.D.; Chirigos, M.A. 1973: Effect of dose and route of Bacillus Calmette-Guérin in chemoimmunostimulation therapy of a murine leukemia Cancer Research 33(8): 1845-1848